Search

Search Constraints

You searched for: Author/Creator McNally, John

Search Results

3. Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus. Issue 1 (24th November 2014)

4. Development of sofosbuvir for the treatment of hepatitis C virus infection. Issue 1 (31st July 2015)

5. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Issue 10292 (19th June 2021)

6. Genome-Wide Association Study to Characterize Serum Bilirubin Elevations in Patients with HCV Treated with Gs-9256, An HCV Ns3 Serine Protease Inhibitor. Issue 7 (October 2014)

7. IDDF2018-ABS-0109 SOFOSBUVIR/VELPATASVIR for 12 weeks in genotype 1–4 hcv-infected liver transplant recipients. (June 2018)

8. IDDF2018-ABS-0110 Efficacy and safety of SOFOSBUVIR/VELPATASVIR plus RIBAVIRIN for 12 or 24 weeks in genotype 1 or 2 HCV-INFECTED japanese patients with prior treatment failure to daa-based regimens. (June 2018)

9. IDDF2018-ABS-0112 Safety and efficacy of sofosbuvir/velpatasvir in a genotype 1–6 hcv infected population from singapore, malaysia, thailand, and vietnam: results from a phase 3, clinical trial. (June 2018)